Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
The standard approach to managing chronic lymphocytic leukemia (CLL) and small lymphocytic
leukemia (SLL) is to wait until you have symptoms before treatment is given.
The goal of this clinical research study is to learn if providing earlier treatment for CLL
or SLL with ibrutinib in patients who do not have symptoms will be more effective than
waiting until symptoms develop.
This is an investigational study. Ibrutinib is FDA approved and commercially available for
the treatment of patients with CLL or SLL. It is considered investigational to give ibrutinib
to CLL and SLL patients before symptoms develop.
The study doctor can describe how the study drug is designed to work.
Up to 50 participants will be enrolled in this study. All will take part at MD Anderson.